HHS.gov @HHSGov
.@Novavax launched a Phase 3 #clinicaltrial for #COVID19 vaccine candidate NVX-CoV2373 funded by @NIH & @BARDA. The investigational vaccine uses a stabilized form of the coronavirus spike protein (which cannot replicate) to induce an immune response. https://t.co/X3s0rx8C5a https://t.co/gqWwQcWHhO — PolitiTweet.org